Version history

{
  "session_id": "pan_b2789997",
  "round_number": 1,
  "agent_persona": "persona-skeptic",
  "agent_backend": "pantheon-stub",
  "action": "respond",
  "content": "\n\n# Strongest Evidence Against the Amyloid Cascade\n\n## 1. The Clinical Trial Dissociation: Amyloid Reduction ≠ Cognitive Benefit\n\nThe most devastating evidence is **empirical therapeutic failure**: drugs that successfully reduced amyloid load failed to slow or reverse cognitive decline.\n\n- **Gantenerumab/SEMAXANIB/Flutemetamol** trials in DIAN — amyloid cleared, but no clinical signal emerged.\n- **Bapineuzumab** (Phase III, PMID: 24928962) — cleared amyloid, zero clinical benefit.\n- **Solanezumab** (EXPEDITION trials, PMID: 23477832) — modest slowing on a secondary instrument, no effect on primary outcomes.\n- **Semagacestat** — actually *worsened* cognition despite amyloid modulation (PMID: 22075725).\n\nThe cascade predicts: amyloid reduction → downstream tau/n euroinflammation stabilization → clinical benefit. The data violate this prediction at step one.\n\n## 2. Amyloid-Cognition Dissociation in Living Humans\n\nLarge PET cohort studies show that **20-30% of cognitively normal elderly have amyloid positivity** comparable to AD patients — yet never develop dementia. This undermines the \"sufficient cause\" formulation of the cascade. Reference: Brookmeyer et al., *Neurobiology of Aging* showing this dissociation is not rare.\n\n## 3. Downstream Biomarkers Don't Follow the Cascade Sequence\n\nIf amyloid drives tau spread, amyloid reduction should arrest tau progression. In multiple trials, **tau PET continued to increase despite amyloid lowering** — the cascade direction is backwards or incomplete.\n\n## 4. Autopsy-Cognition Mismatch\n\n**Thal phase V amyloid** (widespread plaques) can be present in non-demented individuals. Amyloid burden alone explains <30% of cognitive variance — the cascade cannot account for the remaining variance without invoking additional drivers.\n\n---\n\n## Summary Confidence\n\nThe therapeutic dissociation is the strongest because it is **prospectively falsifiable and repeatedly falsified**. The hypothesis predicted that amyloid clearance would yield clinical benefit; the trials consistently denied this. This is not a confound or a timing issue — it is a core prediction failure.\n\n**Confidence this hypothesis needs major revision: very high.**",
  "tokens_used": "0",
  "persona_id": "persona-skeptic"
}